ImmunityBio(US:IBRX) Zhi Tong Cai Jing·2026-01-20 14:32Core Viewpoint - ImmunityBio's stock has surged over 178% this year, with a pre-market increase of over 13% on Tuesday, currently trading at $6.31 per share [1] Group 1: Company Developments - ImmunityBio announced that the FDA is seeking additional information related to its supplemental biologics license application for Anktiva in combination with BCG for treating non-muscle invasive bladder cancer in patients with papillary tumors [1] - The FDA has requested certain additional information to support a potential resubmission of the application initially submitted last year for the papillary indication [1] - The company plans to submit the required information to the FDA within the next 30 days, and the additional information does not involve initiating or designing new clinical trials [1]